Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Market News
ALL ORDINARIES finishes higher Tuesday: 8 shares you missed
Share Market News
Insiders have been buying Altium and 2 other ASX shares this week
⏸️ Investing
8 companies to profit from a falling Australian dollar in 2019
Healthcare Shares
The CSL share price has beaten the ASX 200 by 34% in 2018
Share Fallers
The Mayne Pharma Group share price plunged 8% lower today: Time to invest?
Share Fallers
Why these 4 ASX shares are tumbling lower today
Share Market News
ALL ORDINARIES finishes higher Wednesday: 8 shares you missed
Share Market News
Wednesday's ASX 200 lunch time report
Share Gainers
Mayne Pharma Group share price climbs higher on FDA news: Should you invest?
Share Fallers
Why Coles Group Ltd is among 4 shares falling today
Share Market News
ALL ORDINARIES finishes higher Thursday: 8 shares you missed
Share Fallers
Why these 4 ASX shares are dropping lower today
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
